Segment disclosures

Company overview

Cellular Biomedicine Group, Inc.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

3 dimension combinations 18 retained observations 6 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Biomedicine

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=CMBG:BiomedicineMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-03-3161051 USD20140515Open filing evidence
2013-07-01 – 2013-09-3095365 USD20131226Open filing evidence
2013-01-01 – 2013-09-3095365 USD20131226Open filing evidence
2012-07-01 – 2012-09-304048 USD20131226Open filing evidence
2012-01-01 – 2012-09-30277411 USD20131226Open filing evidence
2012-04-01 – 2012-06-30194774 USD20131206Open filing evidence
2012-01-01 – 2012-06-30273363 USD20131206Open filing evidence
2012-01-01 – 2012-03-3178589 USD20131206Open filing evidence

Consolidated

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=CMBG:ConsolidatedMember
PeriodValueUnitFiledEvidence
2013-04-01 – 2013-06-30111434 USD20131206Open filing evidence
2013-01-01 – 2013-06-30111434 USD20131206Open filing evidence
2012-04-01 – 2012-06-30194774 USD20131206Open filing evidence
2012-01-01 – 2012-06-30273363 USD20131206Open filing evidence
2012-01-01 – 2012-03-3178589 USD20131206Open filing evidence

Consulting

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=CMBG:ConsultingMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-03-311636746 USD20140515Open filing evidence
2013-07-01 – 2013-09-303092985 USD20131226Open filing evidence
2013-01-01 – 2013-09-303204419 USD20131226Open filing evidence
2013-04-01 – 2013-06-30111434 USD20131206Open filing evidence
2013-01-01 – 2013-06-30111434 USD20131206Open filing evidence